Please login to the form below
PharmaMar
This page shows the latest PharmaMar news and features for those working in and with pharma, biotech and healthcare.
NICE recommends two drugs for ovarian cancer but rejects three
But the cost-effectiveness body rejected GlaxoSmithKline's Hycamtin (topotecan), PharmaMar's Yondelis (trabectedin) and Lilly's Gemzar (gemcitabine) for treating the first recurrence of platinum-sensitive ovarian cancer.
Latest news
-
FDA approves Janssen’s Yondelis
Luis Mora, managing director of Janssen's licensing partner PharmaMar, said: “Since Yondelis was first approved in Europe in 2007 approximately 50, 000 patients in 80 countries have benefited from this
-
PharmaMar/J&J’s Yondelis fast-tracked by FDA for sarcoma
Cancer drug could be approved in the US within months. PharmaMar's cancer drug Yondelis could be approved in the US within a few months after it was fast-tracked by ... would be "financially transformative" for PharmaMar's parent company Zeltia.
-
NICE rejection of three ovarian cancer drugs stands
NICE has over the past three years rejected three medicines for the disease: Lilly's Gemzar (gemcitabine), GlaxoSmithKline's Hycamtin (topotecan), both of which are also available as generics, and
-
NICE to update ovarian cancer drug guidelines
However, NICE declined to recommend PharmaMar's Yondelis (trabectedin), as well as the generics gemcitabine and topetecan, as treatments for ovarian cancer that has returned for the first time six months ... The news is less positive for PharmaMar, which
-
Promising new agents for multiple myeloma
Other anti-cancer agents. Plitidepsin (Aplidin; PharmaMar) induces cell death through various cellular pathways. ... PharmaMar received approval from the Independent Data Monitoring Committee (IDMC) in December 2012 to progress the trial to stage II,
More from news
Approximately 1 fully matching, plus 10 partially matching documents found.
Latest appointments
-
Bedrock hires new client services director
Patricia has combined her scientific and commercial understanding to work strategically with both large and small clients, including most recently Novartis, Abbott, Astellas, Bristol-Myers Squibb, PharmaMar and Roche, and we
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Moderna inks R&D agreements with Vertex and Chiesi
- Shionogi's Gram-negative antibiotic launches in the UK
- Eli Lilly reports first results for COVID-19 targeting antibody
- Live Webinar: Medical Modeling in Virtual Reality
- Live Webinar: Telemedicine & the Digitization of Medicine post COVID-19
- Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
- AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
PMHub
OPEN Health
OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
